Merus N.V.
MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumorā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$95.98
Price-0.06%
-$0.06
1Y
Price
Market Cap
$7.279b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1257.1%
EBITDA Margin-1792.2%
Net Profit Margin-785.2%
Free Cash Flow MarginRevenue
$56.228m
+55.6%
1y CAGR+14.5%
3y CAGR+7.0%
5y CAGREarnings
-$385.520m
-79.0%
1y CAGR-45.4%
3y CAGR-58.1%
5y CAGREPS
-$5.57
-66.3%
1y CAGR-26.9%
3y CAGR-37.4%
5y CAGRBook Value
$841.736m
$980.176m
Assets$138.440m
Liabilities$10.999m
DebtDebt to Assets
1.1%
-
Debt to EBITDAFree Cash Flow
-$313.322m
-67.1%
1y CAGR-29.4%
3y CAGR-62.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company